Search Cancer Clinical Trials
Recruiting
This study will assess the safety and tolerability of multiple dose levels of PC14586 in participants with advanced solid tumors containing a p53 Y220C mutation.
- Advanced Solid Tumor
- Advanced Malignant Neoplasm
- Metastatic Cancer
- Metastatic Solid Tumor
- PC14586
Phase 1/Phase 2
Interventional
Primary Outcome:
- Determine the number and type of adverse events to characterize the safety of PC14586
- Establish the maximum tolerated dose (MTD) (Phase 1)
- Establish the Recommended Phase 2 Dose (RP2D) (Phase 1)
- Response rate assessment to evaluate the clinical activity / efficacy of PC14586 (Phase 2)
Secondary Outcome:
- Blood plasma assessment to characterize the pharmacokinetics (PK) of PC14586 and metabolites (Phase 1 and 2)
- Response rate assessment to assess clinical activity / efficacy of PC14586 (Phase 1)
130
October 29, 2020
- Gender: All
- Minimum age: 12 Years
- Maximum age: N/A
- Healthy volunteers: No
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation
NCT04585750
Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.